TALEN CLINICAL TRIALS

All | CRISPR-Cas | ZFN | MegaNuclease

Antibacterial

Blood

Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Acute Lymphoblastic Leukemia, ALL, (NCT02746952)
Sponsors:
Institut de Recherches Internationales Servier
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Acute Lymphoblastic Leukemia, ALL, (NCT02808442)
Sponsors:
Institut de Recherches Internationales Servier
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Human papillomavirus (HPV) related cervical cancer, (NCT03057912)
Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Human papillomavirus (HPV) related cervical cancer, (NCT03226470)
Sponsors:
Huazhong University of Science and Technology
Indicator
IND Enabling
Phase I
Phase II
Phase III
Large B-Cell Lymphoma, LBCL, (NCT04416984)
Sponsors:
Allogene Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (ALLO-605)
Sponsors:
Allogene Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT04093596)
Sponsors:
Allogene Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT04142619)
Sponsors:
Cellectis S.A.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Non-Hodgkin Lymphoma, NHL, (NCT03939026)
Sponsors:
Allogene Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT04696731)
Sponsors:
Allogene Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III

Cancer

Eye

Metabolic disorder

close
Search CRISPR Medicine